Cost-Utility Analysis Of Enzalutamide For Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (Mcrpc) After Failure Of Androgen Deprivation Therapy (Adt)

Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.1266
https://www.valueinhealthjournal.com/article/S1098-3015(15)03342-2/fulltext
Title : Cost-Utility Analysis Of Enzalutamide For Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (Mcrpc) After Failure Of Androgen Deprivation Therapy (Adt)
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03342-2&doi=10.1016/j.jval.2015.09.1266
First page : A474
Section Title : Research Podium Presentations - Session 1 and Session 2
Open access? : No
Section Order : 765
Categories :
Tags :
Regions :
ViH Article Tags :